Reviewed: 2026-04-15 · By the Peptide Protocol editorial team
An honest ranking of the fat-loss peptides that actually have evidence behind them. Ordered by efficacy in human trials, with the trade-offs that product pages usually leave out.
How this list is ordered: by magnitude and quality of clinical evidence for meaningful, sustained fat loss in humans — not by user hype, vendor popularity, or price. Ties are broken by side-effect profile.
The short version
Tirzepatide — currently the most effective fat-loss peptide with robust human data.
Semaglutide — extensive trials, widely available, slightly less weight loss than tirzepatide on average.
Retatrutide — phase 2 data is exceptional, but not yet approved.
Tesamorelin — not primarily a weight-loss drug, but uniquely effective for visceral fat.
AOD-9604 — popular but the human evidence is thin. Ranked low for that reason.
1.
Tirzepatide
ClassDual GLP-1 / GIP receptor agonist
Trial resultUp to ~20.9% body weight loss at 72 weeks (SURMOUNT-1, 15 mg weekly)
FDAApproved (Mounjaro, Zepbound)
CadenceWeekly subcutaneous injection
Tirzepatide is the strongest evidence-based fat-loss peptide available in 2026. Its dual mechanism — hitting both GLP-1 and GIP receptors — produces more weight loss in head-to-head trials than semaglutide, with comparable tolerability once titrated. For most people asking "what peptide works best for fat loss," the answer is this one.
Strengths
Largest mean weight loss of any approved peptide
FDA-approved with extensive safety data
Weekly dosing — low-friction schedule
Strong glycemic improvement alongside fat loss
Trade-offs
Substantial GI side effects during titration
Lean-mass loss is real — pair with resistance training
Compounded forms under FDA scrutiny
Expensive without insurance
Pair with:BPC-157 stack for GI protection during titration.
2.
Semaglutide
ClassGLP-1 receptor agonist
Trial result~14.9% body weight loss at 68 weeks (STEP-1, 2.4 mg weekly)
FDAApproved (Ozempic, Wegovy, Rybelsus)
CadenceWeekly subcutaneous; daily oral (Rybelsus)
Semaglutide is the peptide that made GLP-1 a household category. The evidence base is enormous — multi-year cardiovascular outcome data, a decade of diabetic-population safety data, and a weight-loss indication that changed the standard of care. If tirzepatide is not available or not tolerated, semaglutide is the default alternative.
Trial result~24.2% body weight loss at 48 weeks (phase 2, 12 mg weekly)
FDANot yet approved; phase 3 ongoing
CadenceWeekly subcutaneous
Retatrutide's phase 2 results were stunning — the largest mean weight loss reported for any single pharmaceutical agent. But phase 2 data over-performs phase 3 often enough that the ranking here reflects evidence available in 2026, not projected. If phase 3 results hold, retatrutide becomes the new #1.
Strengths
Largest mean weight loss in phase 2 trials
Triple mechanism may preserve energy expenditure better
Glucagon agonism adds hepatic-fat reduction
Trade-offs
Not FDA-approved; research-use only
Long-term safety data does not yet exist
Phase 3 readouts could change the picture
Limited supply, unclear product quality at research-chem level
FDAApproved (Egrifta) for HIV-associated lipodystrophy
CadenceDaily subcutaneous injection
Tesamorelin is a different category: it doesn't drive large total-body fat loss, but it reliably reduces visceral fat — the metabolically dangerous kind around your organs. For people with stubborn abdominal fat who have already normalized bodyweight, or as an adjunct to GLP-1 therapy to preserve lean mass, tesamorelin has a role nothing else does.
Trial resultSmall phase 2 trials; effect comparable to placebo in the largest study
FDANot approved; failed to meet obesity endpoints
CadenceDaily subcutaneous injection
AOD-9604 is widely sold as a fat-loss peptide, and it is widely recommended in forums. But its clinical record is weak: the compound failed to beat placebo for weight loss in its largest human trial, and development was abandoned as an obesity drug. It's ranked here mainly to explain why — despite its popularity — we don't place it above any of the compounds above.
Strengths
Favorable side-effect profile
Does not raise IGF-1 or blood glucose
Some preclinical lipolysis data
Trade-offs
Failed phase 2b trial for obesity
Popularity exceeds the evidence base
Unclear what "working" AOD-9604 actually is in research-chem supply
What this list leaves out
You'll see peptides ranked on other fat-loss lists that aren't here. A note on each:
Ipamorelin, CJC-1295, Sermorelin, MK-677 — these are GH-axis peptides. They can modestly increase lean mass and marginally shift body composition, but they are not weight-loss drugs in any meaningful sense. Promoting them as fat-loss peptides overstates the evidence.
Frag 176-191 — effectively the same molecule as AOD-9604; same evidence problems.
Melanotan II — reduces appetite modestly but has pigmentation, GI, and cardiovascular side effects that disqualify it from fat-loss recommendations.
MOTS-c — promising preclinical metabolic effects, but no meaningful human weight-loss data yet.
Before you decide anything
Every peptide in this list is either prescription-only or not FDA-approved for weight loss. In the US, Semaglutide and Tirzepatide are approved but require a prescription. Compounded versions exist but are under active FDA scrutiny. Retatrutide and AOD-9604 are not approved. Tesamorelin is approved only for HIV-associated lipodystrophy. Use of any of these for cosmetic weight loss is a clinical conversation — not a research-chem purchase. See our medical review process for how we evaluated this content.
Track your protocol on iPhone
Peptide Protocol logs every dose, tracks side effects, and surfaces patterns — so you can see what's actually working.
Educational use only. Nothing on this page constitutes medical advice or a recommendation to use any specific peptide. Peptide therapy decisions should be made with a licensed healthcare professional who knows your history. Several compounds mentioned here are research-use only or restricted in various jurisdictions.
